Thanks gew59, that makes sense. I had a chance to read the study NCT03073577 "Islet Transplantation Using PKX-100. In the study, it said:
Most importantly, animal studies have shown that the islets treated with PKX-100 were protected from the immunosuppressant (Tac) toxicity and retained their function in animals receiving islet transplant."
In the study:
In light of the beneficial roles of PKX-001 on cellular survival and functionality preservation, our team have evaluated the cytoprotective capacity of PKX-001 in islet transplant, especially its capacity of protection against the diabetogenic effect of Tac.
In vitro assessment of human islets in culture with PKX-001 supplementation has also showed enhanced quality and yield of post-preservation human islets and protection against acute exposure to Tac at clinical relevant doses compared with those without PKX-001 supplementation. Further analysis indicated that islets treated with PKX-001 had decreased oxidative stress, improved insulin release by increasing islet exocytosis, decreased islet loss during preservation due to apoptosis, even in the presence of Tac.
In vivo studies have complemented all in vitro findings above, which demonstrated that PKX-001 supplementation suppressed early inflammation and improved islet engraftment with long-term efficacy.
I didn't find any negative finding in the Islet Transplantation Study, which was very important to my DD research.
